Ventromedial prefrontal neurokinin 1 receptor availability is reduced in chronic pain

Pain

Volumn 149, Issue 1, 2010, Pages 64-70

  Linnman, Clas ^a   Appel, Lieuwe ^b   Furmark, Tomas ^a   Söderlund, Anne ^a,c   Gordh, Torsten ^d   Långström, Bengt ^a,e   Fredrikson, Mats ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b BIACORE AB   (Sweden)

^c MÄLARDALEN UNIVERSITY   (Sweden)

^d Department of Surgical Sciences   (Sweden)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Avoidance; Chronic pain; Neurokinin 1; PET; Substance P; Ventromedial prefrontal cortex; Whiplash

Indexed keywords

CARBON 11; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VOFOPITANT; VOFOPITANT C 11;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; ATTENUATION; AVOIDANCE BEHAVIOR; BRAIN BLOOD FLOW; CHRONIC PAIN; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEAR; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; INSULA; MALE; PERIAQUEDUCTAL GRAY MATTER; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; WHIPLASH INJURY; ZONA INCERTA;

ADULT; CHRONIC DISEASE; DOWN-REGULATION; FEMALE; HUMANS; MALE; PAIN; PREFRONTAL CORTEX; RECEPTORS, NEUROKININ-1; WHIPLASH INJURIES;

EID: 77349122987     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2010.01.008     Document Type: Article

References (58)

1. Alpar E., Onuoha G., Killampalli V.V., and Waters R. Management of chronic pain in whiplash injury. J Bone Joint Surg 84 (2002) 807-811
2. An X., Bandler R., Ongur D., and Price J.L. Prefrontal cortical projections to longitudinal columns in the midbrain periaqueductal gray in macaque monkeys. J Comp Neurol 401 (1998) 455-479
3. Apkarian A.V., Baliki M.N., and Geha P.Y. Towards a theory of chronic pain. Prog Neurobiol 87 (2009) 81-97
4. Apkarian A.V., Bushnell M.C., Treede R.D., and Zubieta J.K. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain (Lond, England) 9 (2005) 463-484
5. Baliki M.N., Chialvo D.R., Geha P.Y., Levy R.M., Harden R.N., Parrish T.B., and Apkarian A.V. Chronic pain and the emotional brain: specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. J Neurosci 26 (2006) 12165-12173
6. Baliki M.N., Geha P.Y., Apkarian A.V., and Chialvo D.R. Beyond feeling: chronic pain hurts the brain, disrupting the default-mode network dynamics. J Neurosci 28 (2008) 1398-1403
7. 11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171--PET studies in rhesus monkey. Neuropharmacology 39 (2000) 664-670
8. Blomeley C.P., Kehoe L.A., and Bracci E. Substance P mediates excitatory interactions between striatal projection neurons. J Neurosci 29 (2009) 4953-4963
9. Carmichael S.T., and Price J.L. Connectional networks within the orbital and medial prefrontal cortex of macaque monkeys. J Comp Neurol 371 (1996) 179-207
10. Crombez G., Vlaeyen J.W., Heuts P.H., and Lysens R. Pain-related fear is more disabling than pain itself: evidence on the role of pain-related fear in chronic back pain disability. Pain 80 (1999) 329-339
11. de Lange R.P., Wiegant V.M., and Stam R. Altered neuropeptide Y and neurokinin messenger RNA expression and receptor binding in stress-sensitised rats. Brain Res 1212 (2008) 35-47
12. Duric V., and McCarson K.E. Neurokinin-1 (NK-1) receptor and brain-derived neurotrophic factor (BDNF) gene expression is differentially modulated in the rat spinal dorsal horn and hippocampus during inflammatory pain. Mol Pain 3 (2007) 32
13. Elliott P.J., and Iversen S.D. Behavioural effects of tachykinins and related peptides. Brain Res 381 (1986) 68-76
14. Freedman L.J., Insel T.R., and Smith Y. Subcortical projections of area 25 (subgenual cortex) of the macaque monkey. J Comp Neurol 421 (2000) 172-188
15. Friston K.J., Buechel C., Fink G.R., Morris J., Rolls E., and Dolan R.J. Psychophysiological and modulatory interactions in neuroimaging. NeuroImage 6 (1997) 218-229
16. Friston K.J., Holmes A.P., Worsley K.J., Poline J.P., Frith C.D., and Frackowiak R.S.J. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2 (1994) 189-210
17. 18F]SPA-RQ. Biol Psychiatry 66 (2009) 94-97
18. Geha P.Y., Baliki M.N., Harden R.N., Bauer W.R., Parrish T.B., and Apkarian A.V. The brain in chronic CRPS pain: abnormal gray-white matter interactions in emotional and autonomic regions. Neuron 60 (2008) 570-581
19. Gracely R.H., Geisser M.E., Giesecke T., Grant M.A., Petzke F., Williams D.A., and Clauw D.J. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain 127 (2004) 835-843
20. Grady E.F., Garland A.M., Gamp P.D., Lovett M., Payan D.G., and Bunnett N.W. Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. Mol Biol Cell 6 (1995) 509-524
21. Gundel H., Valet M., Sorg C., Huber D., Zimmer C., Sprenger T., and Tolle T.R. Altered cerebral response to noxious heat stimulation in patients with somatoform pain disorder. Pain 137 (2008) 413-421
22. Haber S.N., Kunishio K., Mizobuchi M., and Lynd-Balta E. The orbital and medial prefrontal circuit through the primate basal ganglia. J Neurosci 15 (1995) 4851-4867
23. Hasenohrl R.U., Souza-Silva M.A., Nikolaus S., Tomaz C., Brandao M.L., Schwarting R.K., and Huston J.P. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides 34 (2000) 272-280
24. Hietala J., Nyman M.J., Eskola O., Laakso A., Gronroos T., Oikonen V., Bergman J., Haaparanta M., Forsback S., Marjamaki P., Lehikoinen P., Goldberg M., Burns D., Hamill T., Eng W.S., Coimbra A., Hargreaves R., and Solin O. Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol Imaging Biol 7 (2005) 262-272
25. Hill R. NK1 (substance P) receptor antagonists - why are they not analgesic in humans?. Trends Pharmacol Sci 21 (2000) 244-246
26. Kafetzopoulos E., Holzhauer M.S., and Huston J.P. Substance P injected into the region of the nucleus basalis magnocellularis facilitates performance of an inhibitory avoidance task. Psychopharmacology 90 (1986) 281-283
27. Kertes E., Laszlo K., Berta B., and Lenard L. Effects of substance P microinjections into the globus pallidus and central nucleus of amygdala on passive avoidance learning in rats. Behav Brain Res 198 (2009) 397-408
28. Lenard L., and Kertes E. Influence of passive avoidance learning by substance P in the basolateral amygdala. Acta Biol Hung 53 (2002) 95-104
29. Linnman C., Appel L., Soderlund A., Frans O., Engler H., Furmark T., Gordh T., Langstrom B., and Fredrikson M. Chronic whiplash symptoms are related to altered regional cerebral blood flow in the resting state. Eur J Pain (Lond, England) 13 (2009) 65-70
30. Lutz J., Jager L., de Quervain D., Krauseneck T., Padberg F., Wichnalek M., Beyer A., Stahl R., Zirngibl B., Morhard D., Reiser M., and Schelling G. White and gray matter abnormalities in the brain of patients with fibromyalgia: a diffusion-tensor and volumetric imaging study. Arthritis Rheum 58 (2008) 3960-3969
31. Mai J.K., Assheuer J., and Paxinos G. Atlas of the human brain (1997), Academic Press, San Diego
32. Maldjian J.A., Laurienti P.J., Kraft R.A., and Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. NeuroImage 19 (2003) 1233-1239
33. May A. Chronic pain may change the structure of the brain. Pain 137 (2008) 7-15
34. McFarland N.R., and Haber S.N. Thalamic relay nuclei of the basal ganglia form both reciprocal and nonreciprocal cortical connections, linking multiple frontal cortical areas. J Neurosci 22 (2002) 8117-8132
35. Michelgard A., Appel L., Pissiota A., Frans O., Langstrom B., Bergstrom M., and Fredrikson M. Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry 61 (2007) 1002-1006
36. Milad M.R., and Quirk G.J. Neurons in medial prefrontal cortex signal memory for fear extinction. Nature 420 (2002) 70-74
37. Milad M.R., Wright C.I., Orr S.P., Pitman R.K., Quirk G.J., and Rauch S.L. Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. Bio. Psychiatry 62 (2007) 446-454
38. Mobbs D., Petrovic P., Marchant J.L., Hassabis D., Weiskopf N., Seymour B., Dolan R.J., and Frith C.D. When fear is near: threat imminence elicits prefrontal-periaqueductal gray shifts in humans. Science (New York, NY 317 (2007) 1079-1083
39. Nagel J.A., and Huston J.P. Enhanced inhibitory avoidance learning produced by post-trial injections of substance P into the basal forebrain. Behav Neural Biol 49 (1988) 374-385
40. 18F]SPA-RQ. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale. Neuropsychopharmacologicum (CINP) 10 (2007) 219-229
41. Ochsner K.N., Ludlow D.H., Knierim K., Hanelin J., Ramachandran T., Glover G.C., and Mackey S.C. Neural correlates of individual differences in pain-related fear and anxiety. Pain 120 (2006) 69-77
42. Patlak C.S., and Blasberg R.G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 5 (1985) 584-590
43. Picavet H.S., Vlaeyen J.W., and Schouten J.S. Pain catastrophizing and kinesiophobia: predictors of chronic low back pain. Am J Epidemiol 156 (2002) 1028-1034
44. Ploghaus A., Becerra L., Borras C., and Borsook D. Neural circuitry underlying pain modulation: expectation, hypnosis, placebo. Trends Cogn Sci 7 (2003) 197-200
45. Rupniak N.M., Carlson E., Boyce S., Webb J.K., and Hill R.G. Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733, 060 in gerbils. Pain 67 (1996) 189-195
46. Rupniak N.M., Webb J.K., Williams A.R., Carlson E., Boyce S., and Hill R.G. Antinociceptive activity of the tachykinin NK1 receptor antagonist, CP-99, 994, in conscious gerbils. Br J Pharmacol 116 (1995) 1937-1943
47. Russell I.J., Orr M.D., Littman B., Vipraio G.A., Alboukrek D., Michalek J.E., Lopez Y., and MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37 (1994) 1593-1601
48. Spielberger C., Gorsuch R., and Lushene R. Manual for the state-trait anxiety inventory (1970), Consulting Psychologists Press, Palo Alto, CA
49. Spitzer W.O., Skovron M.L., Salmi L.R., Cassidy J.D., Duranceau J., Suissa S., and Zeiss E. Scientific monograph of the Quebec task force on whiplash-associated disorders: redefining "whiplash" and its management. Spine 20 (1995) 1S-73S
50. Stockmeier C.A., Shi X., Konick L., Overholser J.C., Jurjus G., Meltzer H.Y., Friedman L., Blier P., and Rajkowska G. Neurokinin-1 receptors are decreased in major depressive disorder. Neuroreport 13 (2002) 1223-1227
51. Swinkels-Meewisse E.J., Swinkels R.A., Verbeek A.L., Vlaeyen J.W., and Oostendorp R.A. Psychometric properties of the Tampa scale for kinesiophobia and the fear-avoidance beliefs questionnaire in acute low back pain. Man Ther 8 (2003) 29-36
52. Talairach J., and Tournoux P. Co-planar stereotaxic atlas of the human brain (1988), Georg Thieme Verlag, Stuttgart
53. Vaeroy H., Helle R., Forre O., Kass E., and Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 32 (1988) 21-26
54. Vernon H., and Mior S. The neck disability index: a study of reliability and validity. J Manipulative Physiol Ther 14 (1991) 409-415
55. Vogt B.A. Pain and emotion interactions in subregions of the cingulate gyrus. Nat Rev Neurosci 6 (2005) 533-544
56. Zhao Z., Yang Y., Walker D.L., and Davis M. Effects of substance P in the amygdala, ventromedial hypothalamus, and periaqueductal gray on fear-potentiated startle. Neuropsychopharmacology (2008)
57. Wicksell R.K., Ahlqvist J., Bring A., Melin L., and Olsson G.L. Can exposure and acceptance strategies improve functioning and life satisfaction in people with chronic pain and whiplash-associated disorders (WAD)? a randomized controlled trial. Cogn Behav Ther 37 (2008) 1-14
58. Woods M.P., and Asmundson G.J. Evaluating the efficacy of graded in vivo exposure for the treatment of fear in patients with chronic back pain: a randomized controlled clinical trial. Pain 136 (2008) 271-280